The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Role of Corticosteroids in Drug-Induced Liver Injury. A Systematic Review
Abstract
Introduction: Apart from cessation of the implicated agent leading to drug-induced liver injury (DILI), there is no standard therapy for DILI. Corticosteroids have been used in DILI, although their efficacy is unclear. Published data showed either beneficial effects or no improvement associated with steroid therapy. The aim of the current study was to perform a systematic review of the role of corticosteroids in the treatment of DILI. Methods: A search was performed in PubMed, searching for the terms: “corticosteroids” and “drug-induced liver injury”. Observation studies were included, but case reports excluded. Results: A total of 24 papers were retrieved. Most of these were observational studies on the effects of corticosteroids in moderate/severe DILI (n = 8), reports on the corticosteroid treatment in patients with drug-induced autoimmune hepatitis (DI-AIH) (n = 5), and effects of corticosteroids in drug-induced fulminant acute liver failure (ALF, n = 2). Furthermore, treatment of corticosteroids in patients with liver injury due to check point inhibitors (CPIs) was addressed in nine studies. In moderate/severe DILI, six out of eight studies suggested steroid treatment to be beneficial, whereas two studies showed negative results. All five observational studies on the effects of corticosteroids in DI-AIH showed good therapeutic response with rapid and long lasting effects after discontinuation of corticosteroids and without evidence of relapse. Steroid therapy was not associated with improved overall survival in patients with drug-induced fulminant ALF. CPIs-induced liver injury was found to improve spontaneously in 33–50% without corticosteroids, and the rate of patients who were treated responded to steroids in 33–100% (mean 72%). Conclusions: The majority of studies analyzing the effects of corticosteroids in moderate/severe DILI have demonstrated beneficial effects. However, this was not the case in drug-induced fulminant ALF. Patients with DI-AIH had an excellent response to corticosteroids. The majority of those with CPIs-induced liver injury responded to corticosteroids; however, patients without treatment usually recovered spontaneously. The observational design and comparison with historical controls in these studies makes it very difficult to draw conclusions on the efficacy of corticosteroids in DILI. Therefore, there is a strong need for a randomized controlled trial to properly assess the role of corticosteroids in DILI.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Data on corticosteroid use in DILI is scarce with no randomized controlled studies to evaluate their efficacy and safety; however, there are reports of corticosteroids having beneficial effects in patients with moderate or severe DILI.[18,23]”
From Drug-induced liver injury: Diagnosis, management and the role of liver transplantation (2025) · cites this paper as [23]
In the citing paper
“Data on corticosteroid use in DILI is scarce with no randomized controlled studies to evaluate their efficacy and safety; however, there are reports of corticosteroids having beneficial effects in patients with moderate or severe DILI.[18,23]”
From Drug-induced liver injury: Diagnosis, management and the role of liver transplantation (2025) · cites this paper as [23]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Brahmer, J. R., Lacchetti, C., Schneider, B. J., Atkins, M. B., Brassil, K. J., Caterino, J. M., Chau, I., Ernstoff, M. S., Gardner, J. M., Ginex, P., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.77.6385 · Cited by 3,713
Haanen, J. B. A. G., Carbonnel, F., Robert, C., Kerr, K. M., Peters, S., Larkin, J., & Jordan, K. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx225 · Cited by 2,367
Ostapowicz, G., Fontana, R. J., Schiødt, F. V., Larson, A., Davern, T. J., Han, S. H. B., McCashland, T. M., Shakil, A. O., Hay, J. E., Hynan, L., et al. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-12-200212170-00007 · Cited by 2,227
on behalf of the Society for Immunotherapy of Cancer Toxicity Management Working Group, Puzanov, I., Diab, A., Abdallah, K., Bingham, C. O., Brogdon, C., Dadu, R., Hamad, L., Kim, S., Lacouture, M. E., et al. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0300-z · Cited by 1,992
EASL Clinical Practice Guidelines: autoimmune hepatitis
(2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.06.030 · Cited by 1,245
Drug-Induced Acute Liver Failure: Results of a U.S. Multicenter, Prospective Study
Reuben, A., Koch, D. G., & Lee, W. M. (2010) · Hepatology · doi:10.1002/hep.23937 · Cited by 772
Chalasani, N., Fontana, R. J., Bonkovsky, H. L., Watkins, P. B., Davern, T., Serrano, J., Yang, H., & Rochon, J. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.09.011 · Cited by 755
Drug-induced liver injury—types and phenotypes
Hoofnagle, J. H., & Björnsson, E. S. (2019) · New England Journal of Medicine · doi:10.1056/nejmra1816149 · Cited by 652
Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors
De Martin, E., Michot, J.-M., Papouin, B., Champiat, S., Mateus, C., Lambotte, O., Roche, B., Antonini, T. M., Coilly, A., Laghouati, S., et al. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.01.033 · Cited by 520
Faje, A. T., Lawrence, D., Flaherty, K., Freedman, C., Fadden, R., Rubin, K., Cohen, J., & Sullivan, R. J. (2018) · Cancer · doi:10.1002/cncr.31629 · Cited by 486
Drug-induced autoimmune hepatitis: clinical characteristics and prognosis
Björnsson, E., Talwalkar, J., Treeprasertsuk, S., Kamath, P. S., Takahashi, N., Sanderson, S., Neuhauser, M., & Lindor, K. (2010) · Hepatology · doi:10.1002/hep.23588 · Cited by 436
Self-citationHaanen, J. B. A. G., Carbonnel, F., Robert, C., Kerr, K. M., Peters, S., Larkin, J., & Jordan, K. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy162 · Cited by 431
Pollack, M. H., Betof, A., Dearden, H., Rapazzo, K., Valentine, I., Brohl, A. S., Ancell, K. K., Long, G. V., Menzies, A. M., Eroglu, Z., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdx642 · Cited by 393 · cited 1×
“In two studies, 14–17% of patients having been treated with steroids exhibited a recurrence of hepatotoxicity after tapering steroids (Pollack et al., 2018; Miller et al., 2020).”
BackgroundSuzuki, A., Brunt, E. M., Kleiner, D. E., Miquel, R., Smyrk, T. C., Andrade, R. J., Lucena, I. M., Castiella, A., Lindor, K., & Björnsson, E. (2011) · Hepatology · doi:10.1002/hep.24481 · Cited by 310
Self-citationAutoimmune acute liver failure: Proposed clinical and histological criteria
Stravitz, R. T., Lefkowitch, J. H., Fontana, R. J., Gershwin, M. E., Leung, P. S. C., Sterling, R. K., Manns, M. P., Norman, G. L., Lee, W. M., & and the Acute Liver Failure Study Group (2011) · Hepatology · doi:10.1002/hep.24080 · Cited by 303
Del Castillo, M., Romero, F. A., Argüello, E., Kyi, C., Postow, M. A., & Redelman-Sidi, G. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw539 · Cited by 294
Kirk, A. P., Jain, S., Pocock, S., Thomas, H. C., & Sherlock, S. (1980) · Gut · doi:10.1136/gut.21.1.78 · Cited by 285
Corticosteroids can reverse severe imatinib-induced hepatotoxicity.
Ljungman, P. T., Perez-Bercoff, L., Jonsson, J., Avetisyan, G., Sparrelid, E., Aschan, J., Barkholt, L., Larsson, K., Winiarski, J., Yun, Z., et al. (2006) · PubMed · Cited by 245
Steroid Use in Acute Liver Failure
Karkhanis, J., Verna, E. C., Chang, M. S., Stravitz, R. T., Schilsky, M. L., Lee, W. M., & Brown, R. S. (2013) · Hepatology · doi:10.1002/hep.26678 · Cited by 196
Liver Injury From Tumor Necrosis Factor-α Antagonists: Analysis of Thirty-four Cases
Ghabril, M., Bonkovsky, H. L., Kum, C., Davern, T., Hayashi, P. H., Kleiner, D. E., Serrano, J., Rochon, J., Fontana, R. J., & Bonacini, M. (2013) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2012.12.025 · Cited by 196
Acute liver failure in Sweden: etiology and outcome
Wei, G., Bergquist, A. M., Broomé, U., Lindgren, S. C., Wallerstedt, S. M., Almer, S. H., Sangfelt, P., Danielsson, A., Sandberg–Gertzén, H., Lööf, L., et al. (2007) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2007.01818.x · Cited by 185
Fulminant drug-induced hepatic failure leading to death or liver transplantation in Sweden
Björnsson, E., Jerlstad, P., Bergqvist, A., & Olsson, R. (2005) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365520510023846 · Cited by 123
Self-citationA double-blinded, randomized trial of hydrocortisone in acute hepatic failure
Rakela, J. L., Mosley, J. W., Edwards, V. M., Govindarajan, S., Alpert, E., & The Acute Hepatic Failure Study Group (1991) · Digestive Diseases and Sciences · doi:10.1007/bf01307513 · Cited by 120
Risk of drug-induced liver injury from tumor necrosis factor antagonists
Björnsson, E. S., Gunnarsson, B. I., Gröndal, G., Jonasson, J. G., Einarsdottir, R., Ludviksson, B. R., Gudbjörnsson, B., & Olafsson, S. (2015) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2014.07.062 · Cited by 118
Self-citationBMJ Publishing Group Ltd and British Society of Gastroenterology (1979) · Gut · doi:10.1136/gut.20.7.620 · Cited by 108
A common constitutional JAK2 haplotype predisposes to Myeloprolifrative Neoplasms
Žvirblis, T., Ivanauskaitė, V., Tavorienė, I., Gerbutavičius, R., Juozaitytė, E., Malciūtė, L., Jurgutis, M., Daubarienė, J., Ramanauskienė, D., Ragelienė, L., et al. (2009) · ePrints Soton (University of Southampton) · doi:10.3324/%25x · Cited by 108
Immunotherapy-related hepatitis: real-world experience from a tertiary centre
Cheung, V., Gupta, T., Payne, M., Middleton, M. R., Collier, J. D., Simmons, A., Klenerman, P., Brain, O., & Cobbold, J. (2019) · Frontline Gastroenterology · doi:10.1136/flgastro-2018-101146 · Cited by 104
The significance of autoantibodies and immunoglobulins in acute liver failure: A cohort study
Bernal, W. E., Ma, Y., Smith, H. M., Portmann, B. C., Wendon, J. A., & Vergani, D. (2007) · Journal of Hepatology · doi:10.1016/j.jhep.2007.05.011 · Cited by 101
Huffman, B. M., Kottschade, L. A., Kamath, P. S., & Markovic, S. N. (2018) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000000374 · Cited by 100
Immune-related hepatitis with immunotherapy: Are corticosteroids always needed?
Gauci, M.-L., Baroudjian, B., Zeboulon, C., Pagès, C., Poté, N., Roux, O., Bouattour, M., & Lebbé, C. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.034 · Cited by 100
Autoimmune hepatitis and anti-tumor necrosis factor alpha therapy: a single center report of 8 cases
Rodrigues, S. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i24.7584 · Cited by 97
Clinical Characteristics and Adverse Impact of Hepatotoxicity due to Immune Checkpoint Inhibitors
Miller, E., Abu‐Sbeih, H., Styskel, B. A., Nogueras‐González, G. M., Blechacz, B. R. A., Naing, A., & Chalasani, N. (2019) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000000398 · Cited by 96
Steroid and Ursodesoxycholic Acid Combination Therapy in Severe Drug-Induced Liver Injury
Wree, A., Dechêne, A., Herzer, K., Hilgard, P., Syn, W.-K., Gerken, G., & Canbay, A. (2011) · Digestion · doi:10.1159/000322298 · Cited by 93
Björnsson, E. S., Bergmann, O., Jonasson, J. G., Grondal, G., Gudbjornsson, B., & Olafsson, S. (2017) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2017.05.027 · Cited by 84
Self-citationBjörnsson, H. K., Gudbjornsson, B., & Björnsson, E. S. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2021.08.024 · Cited by 70
Self-citationBiologic and checkpoint inhibitor‐induced liver injury: a systematic literature review
Shah, P., Sundaram, V., & Björnsson, E. (2020) · Hepatology Communications · doi:10.1002/hep4.1465 · Cited by 64
Immune-related hepatitis related to checkpoint inhibitors: clinical and prognostic factors
Riveiro‐Barciela, M., Barreira‐Díaz, A., Vidal‐González, J., Muñoz‐Couselo, E., Martínez‐Valle, F., Viladomiu, L., Mínguez, B., Ortiz‐Velez, C., Castells, L., Esteban, R., et al. (2020) · Liver International · doi:10.1111/liv.14489 · Cited by 62
A controlled trial of steroid therapy in massive hepatic necrosis.
Ware, A. J., Jones, R. E., Shorey, J. W., & Combes, B. (1974) · PubMed · Cited by 61
Incidence of grade 3-4 liver injury under immune checkpoints inhibitors: A retrospective study
Parlati, L., Vallet‐Pichard, A., Batista, R., Hernvann, A., Sogni, P., Pol, S., & Mallet, V. O. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.08.014 · Cited by 53
Weber, S., Benesic, A., Rotter, I., & Gerbes, A. L. (2019) · Liver International · doi:10.1111/liv.14195 · Cited by 53
Beneficial effect of corticosteroids for patients with severe drug‐induced liver injury
Hu, P. F., Wang, P. Q., Chen, H., Hu, X. F., Xie, Q. P., Shi, J., Lin, L., & Xie, W. F. (2016) · Journal of Digestive Diseases · doi:10.1111/1751-2980.12383 · Cited by 50
Kitagataya, T., Suda, G., Nagashima, K., Katsurada, T., Yamamoto, K., Kimura, M., Maehara, O., Yamada, R., Shigesawa, T., Suzuki, K., et al. (2020) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.15041 · Cited by 49
Hospital Admissions for Drug-Induced Liver Injury: Clinical Features, Therapy, and Outcomes
Hou, F.-Q., Zeng, Z., & Wang, G. (2012) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-012-9373-y · Cited by 45
Ito, T., Ishigami, M., Yamamoto, T., Mizuno, K., Yamamoto, K., Imai, N., Ishizu, Y., Honda, T., Kawashima, H., Yasuda, S., et al. (2021) · Hepatology International · doi:10.1007/s12072-021-10238-y · Cited by 40
Gauci, M.-L., Baroudjian, B., Bédérède, U., Zeboulon, C., Delyon, J., Allayous, C., Madelaine, I., Eftekhari, P., Resche‐Rigon, M., Poté, N., et al. (2020) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2020.06.016 · Cited by 34
Pang, L., Yang, W., & Hou, F.-Q. (2017) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2017.08.003 · Cited by 30
Borlak, J. T., van Bömmel, F., & Berg, T. (2017) · Liver International · doi:10.1111/liv.13538 · Cited by 29
Wan, Y.-M., Wu, J.-F., Li, Y.-H., Wu, H.-M., Wu, X.-N., & Xu, Y. (2019) · Medicine · doi:10.1097/md.0000000000015886 · Cited by 25
Drug induced liver injury: from pathogenesis to liver transplantation
Germani, G., Battistella, S., Ulinici, D., Zanetto, A., Shalaby, S., Pellone, M., Gambato, M., Senzolo, M., Russo, F. P., & Burra, P. (2021) · Minerva Gastroenterology · doi:10.23736/s2724-5985.20.02795-6 · Cited by 20
Cited by
Andrade, R. J., Aithal, G. P., de Boer, Y. S., Liberal, R., Gerbes, A., Regev, A., Terziroli Beretta-Piccoli, B., Schramm, C., Kleiner, D. E., De Martin, E., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.04.033 · Cited by 166
Self-citationBjörnsson, E. S., Stephens, C., Atallah, E., Robles‐Diaz, M., Alvarez‐Alvarez, I., Gerbes, A., Weber, S., Stirnimann, G., Kullak‐Ublick, G., Cortez‐Pinto, H., et al. (2023) · Liver International · doi:10.1111/liv.15378 · Cited by 69
Self-citationDrug-induced liver injury: Diagnosis, management and the role of liver transplantation
Ozturk, N. B., Uskudar, E., Toruner, M. D., Simsek, C., & Gurakar, A. (2025) · Hepatology Forum · doi:10.14744/hf.2024.2024.0003 · Cited by 9
The contemporary epidemiology, causes, and management of drug-induced liver injury
Swanson, L., & Fontana, R. J. (2026) · Hepatology Communications · doi:10.1097/hc9.0000000000001011
Metadata
- Authors
- Björnsson, E. S., Vucic, V., Stirnimann, G., & Robles-Díaz, M.
- Venue
- Frontiers in Pharmacology
- Publisher
- Frontiers Media SA
- Published
- 2022-02-10
- Volume
- 13
- ISSN
- 1663-9812
- PMC
- PMC8867035
- Cited by
- 62
- References
- 49
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
